VLS Tirzepatide 20mg Pen – Mid-Dose GLP-1 + GIP Therapy

VLS Tirzepatide 20mg – is a powerful dual-incretin peptide that activates both GIP and GLP-1 receptors, supporting advanced metabolic research. Developed by Vitality Life Science (VLS), this compound is designed for studies focused on weight loss, insulin sensitivity, and glucose control.

With a 20mg concentration per vial, VLS Tirzepatide offers a balance between potency and precision. It is produced in sterile, GMP-compliant environments, ensuring consistent results for high-quality research. Ideal for projects investigating dual-pathway mechanisms in diabetes and obesity treatment models.

Key Features:

Dual-action GIP/GLP-1 receptor agonist
20mg per vial – mid-range potency
Pharmaceutical-grade quality from VLS
Trusted for weight and glucose regulation studies

How to Use VLS Tirzepatide:
Form: Injectable peptide

Dosage: Start with 0.5 mg per week, gradually increase to 2.5–5 mg per week based on tolerance

Cycle Length: 8–16 weeks, followed by a 4-week break

Administration: Subcutaneous injection, once weekly

How It Works:

GIP Agonism: Enhances insulin secretion and promotes fat breakdown.
GLP-1 Agonism: Reduces appetite, slows gastric emptying, and improves blood sugar control.

Both actions combined help optimize fat metabolism and reduce hunger, making it easier to maintain a calorie deficit.

Recommended Stacks:
Pair With:

Synedica Semaglutide for appetite control and metabolic support

Synedica Tirzepatide for enhanced fat loss

Retatrutide for aggressive fat-burning and metabolic benefits